Passer à la navigation principale Passer à la recherche Passer au contenu principal

FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA

  • Daimel Castillo-González
  • , Gisselle Pérez-Machado
  • , Aurore Guédin
  • , Jean Louis Mergny
  • , Miguel Angel Cabrera-Pérez
  • Department of Pharmacy
  • Central University of Las Villas
  • Molecular Simulation and Drug Design Group
  • Univ. Bordeaux
  • Univ. Bordeaux
  • IECB

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

22 Citations (Scopus)

Résumé

Guanine-rich sequences found in telomeres and oncogene promoters have the ability to form G-quadruplex structures. In this paper we describe the use of a virtual screening assay to search a database of FDA-approved compounds for compounds with the potential to bind G-quadruplex DNA. More than 750 telomerase inhibitors were identified in a literature search as acting through G-quadruplex stabilization, and from evaluation of these compounds, theoretical models capable of discriminating new compounds that bind Gquadruplex DNA were developed. Six compounds predicted to bind to the G-quadruplex structure were tested for their ability to bind to the human telomeric DNA sequence. Prochloroperazine, promazine, and chlorpromazine stabilized the G-quadruplex structure as determined by fluorescence resonance energy transfer techniques. These compounds also bound to promoter sequences of oncogenes such as c-myc and K-ras. Amitriptyline, imipramine, and loxapine were less stabilizing but did bind to the G-quadruplex. The ability of prochloroperazine, promazine, and chlorpromazine to recognize G-quadruplex structures was confirmed using a fluorescent intercalator displacement assay, in which displacement of thiazole orange from G-quadruplex structures was demonstrated. Interestingly, these compounds exhibited selectivity for the G-quadruplex structure as all had poor affinity for the duplex sequence.

langue originaleAnglais
Pages (de - à)2164-2173
Nombre de pages10
journalCurrent Pharmaceutical Design
Volume19
Numéro de publication12
Les DOIs
étatPublié - 21 mai 2013
Modification externeOui

Empreinte digitale

Examiner les sujets de recherche de « FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation